Drugs / SNP318
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05792163 | Mar → Nov 2023 | Alzheimer disease | SciNeuro | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07199777 | Nov 2025 → Nov 2026 expected | diabetic macular edema | SciNeuro | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-11-30 | SciNeuro | Results SciNeuro completes dosing in its Phase 1 clinical trial of SNP318, an oral therapeutic for Alzheimer’s disease and other neurodegenerative diseases scineuro.com ↗
Administration of SNP318 was well-tolerated with a favorable exposure, strong target engagement, and excellent safety profile. |
All press releases naming this drug 2 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNP318 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07199777 ↗ |
| Action | Inhibit | “selective inhibitor of Lp-PLA2” NCT07199777 ↗ |
| Modality | Small molecule | “SNP318 is a small molecule and selective inhibitor of Lp-PLA2.” NCT07199777 ↗ |
| Route | Oral | “Route of administration: Oral” NCT05792163 ↗ |